-
公开(公告)号:WO2012009699A3
公开(公告)日:2012-03-15
申请号:PCT/US2011044283
申请日:2011-07-15
Applicant: ABBOTT LAB , SHEKHAR SHASHANK , FRANCZYK THADDEUS S , BARNES DAVID M , DUNN TRAVIS B , HAIGHT ANTHONY R , CHAN VINCENT S
Inventor: SHEKHAR SHASHANK , FRANCZYK THADDEUS S , BARNES DAVID M , DUNN TRAVIS B , HAIGHT ANTHONY R , CHAN VINCENT S
IPC: C07D239/54 , A61K31/522 , A61P31/14 , B01J31/24
CPC classification number: C07D239/54 , A61K31/513 , A61K31/7056 , A61K38/21 , A61K45/06 , B01J31/2423 , B01J2231/344 , B01J2231/4227 , B01J2231/4283 , B01J2231/4288 , B01J2231/4294 , B01J2531/824 , A61K2300/00
Abstract: This disclosure is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions.
Abstract translation: 本公开涉及:(a)制备其特别是可用于抑制丙型肝炎病毒(HCV)的化合物及其盐的方法; (b)可用于制备化合物和盐的中间体; (c)包含该化合物或其盐的药物组合物; 和(d)使用这种组合物的方法。
-
公开(公告)号:CA2750125A1
公开(公告)日:2010-08-19
申请号:CA2750125
申请日:2010-02-09
Applicant: ABBOTT LAB
Inventor: SHEKHAR SHASHANK , YU SU , HAIGHT ANTHONY R , CHMURA PRESTON E , KISHORE VIMAL
IPC: A61K31/135
Abstract: Disclosed herein are methods of making compounds which are agonists or antagonists of one or more of the individual receptors of the S1P receptor family.
-
公开(公告)号:CA2727932A1
公开(公告)日:2009-12-23
申请号:CA2727932
申请日:2009-06-18
Applicant: ABBOTT LAB
Inventor: FRANCZYK THADDEUS S II , HILL DAVID R , HAIGHT ANTHONY R , MCLAUGLIN MAUREEN ANN , SHEKHAR SHASHANK , YU SU , MEI JIANZHANG , WANG LEI
IPC: C07D295/155
Abstract: A process for the preparation of the apoptosis promoter N-(4-(4-((2-(4-chlorophenyl)-5,5- dimethyl- 1 -cyclohex- 1 -en- 1 -yl)methyl)piperazin- 1 -yl)benzoyl)-4-((( 1 R)-3-(morpholin-4-yl)- 1-((phenylsulfanyl) methyl)propyl)amino)-3-(trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263). Formula (I).
-
公开(公告)号:ES2423668T3
公开(公告)日:2013-09-23
申请号:ES10720502
申请日:2010-05-20
Applicant: ABBOTT LAB , ABBOTT GMBH & CO KG , ABBVIE INC
Inventor: WELCH DENNIE S , AKRITOPOULOU-ZANZE IRINI , BRAJE WILFRIED , DJURIC STEVAN W , WILSON NOEL S , TURNER SEAN C , KRUGER ALBERT W , RELO ANA-LUCIA , SHEKHAR SHASHANK , ZHAO HONGYU , GANDARILLA JORGE , GASIECKI ALAN F , LI HUANQIU , THOMPSON CHRISTINA M , ZHANG MIN
IPC: C07D487/04 , A61K31/551 , A61K31/553 , A61K31/554 , A61P25/00 , C07D491/04 , C07D495/04
Abstract: Un compuesto de fórmula (I):**Fórmula** o una sal farmacéuticamente aceptable del mismo,donde A está seleccionado entre el grupo que consiste en R1, R3, R4, y R5 están seleccionados independientemente entre el grupo que consiste en hidrógeno, alquenilo, alquilo, haloalquilo, G1, G2, -(CR4aR5a)m-G1, y -(CR4aR5a)m-G2; R4a y R5a, en cada caso, cada uno es independientemente hidrógeno, halógeno, alquilo, o haloalquilo; G1, en cada caso, es independientemente arilo o heteroarilo, donde cada G1 está independientemente sin sustituir osustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados entre el grupo que consiste en alquilo, alquenilo, alquinilo,halógeno, ciano, -NO2, -OR1b, -OC(O)R1b, -OC(O)N(Rb)(R3b), -SR1b, -S(O)R2b, -S(O)2R2b, -S(O)2N(Rb)(R3b), -C(O)R1b,-C(O)OR1b, -C(O)N(Rb)(R3b), -N(Rb)(R3b), -N(Ra)C(O)R1b, -N(Ra)C(O)O(R1b), -N(Ra)C(O)N(Rb)(R3b), -(CR4bR5b)m-NO2,-N(Rb)S(O)2(R2b), -(CR4bR5b)m-OR1b, -C(OH)[(CR4bR5b)m-R4b]2, -(CR4bR5b)m-OC(O)R1b, -(CR4bR5b)m-OC(O)N(Rb)(R3b), -(CR4bR5b)m-SR1b, -(CR4bR5b)m-S(O)R2b, -(CR4bR5b)m-S(O)2R2b, -(CR4bR5b)m-S(O)2N(Rb)(R3b),-(CR4bR5b)m-C(O)R1b, -(CR4bR5b)m-C(O)OR1b, -(CR4bR5b)m-C(O)N(Rb)(R3b), -(CR4bR5b)m-N(Rb)(R3b), -(CR4bR5b)m-N(Ra)C(O)R1b, -(CR4bR5b)m-N(Ra)C(O)O(R1b), -(CR4bR5b)m-N(Ra)C(O)N(Rb)(R3b), -(CR4bR5b)m-N(Rb)S(O)2(R2b),cianoalquilo, y haloalquilo.
-
公开(公告)号:ES2409263T3
公开(公告)日:2013-06-26
申请号:ES09767695
申请日:2009-06-18
Applicant: ABBOTT LAB
Inventor: FRANCZYK THADDEUS , HILL DAVID , HAIGHT ANTHONY , MCLAUGLIN MAUREEN , SHEKHAR SHASHANK , YU SU , MEI JIANZHANG , WANG LEI
IPC: C07D295/13 , C07D295/155
Abstract: Un procedimiento para elaborar N-(4-(4-((2-(4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1-il)benzoil)-4-(((1R)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino)-3-((trifluorometil)sulfonil)bencenosulfonamida,o una de sus sales farmacéuticamente aceptables, que comprende: (e) hacer reaccionar el 2-(4-clorofenil)-5,5-dimetilciclohex-1-eno-1-carbaldehído, 4-piperazin-1-ilbenzoato de etilo yun primer agente reductor y aislar o no aislar el 4-(4-((2-(4-clorofenil)-5,5-dimetilciclohex-1-en-1-il)metil)piperazin-1-il)benzoato de etilo; (f) hacer reaccionar el 4-(4-((2-(4-clorofenil)-5,5-dimetilciclohex-1-en-1-il)metil)piperazin-1-il)benzoato de etilo y unatercera base acuosa, y aislar o no aislar el ácido 4-(4-((2-(4-clorofenil)-5,5-dimetilciclohex-1-en-1-il)metil)piperazin-1-il)benzoico; y (g) hacer reaccionar el ácido 4-(4-((2-(4-clorofenil)-5,5-dimetilciclohex-1-en-1-il)metil)piperazin-1-il)benzoico, 4-(((1R)-3-morfolin-4-il-1-((feniltio)metil)propil)amino)-3-((trifluorometil)sulfonil)bencenosulfonamida y un primer reactivo deacoplamiento con o sin una cuarta base y con o sin un reactivo de acoplamiento auxiliar, y aislar o no aislar la N-(4-(4-((2-(4-clorofenil)-4,5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1-il)benzoil)-4-(((1R)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino)-3-((trifluorometil)sulfonil)bencenosulfionamida.
-
公开(公告)号:NZ589732A
公开(公告)日:2012-08-31
申请号:NZ58973209
申请日:2009-06-18
Applicant: ABBOTT LAB
Inventor: FRANCZYK THADDEUS S , HILL DAVID R , HAIGHT ANTHONY R , MCLAUGLIN MAUREEN ANN , SHEKHAR SHASHANK , YU SU , MEI JIANZHANG , WANG LEI
IPC: C07D295/155 , C07D295/023
Abstract: Disclosed A process for making ABT-263 (7) an apoptosis promoter having the proper chemical name: N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, comprising: (a) reacting 4,4-dimethylcyclohexanone, an alkyl formate and a first base to provide (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone and isolating or not isolating the (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone; (b) reacting the (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone, a second base and a first silyl ether protecting group reagent to provide a first protected (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone and isolating or not isolating the first protected (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone; (c) reacting the first protected (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone and 4-chlorophenyl magnesium bromide to provide the first protected (2E)-1-(4-chlorophenyl)-2-(hydroxymethylene)-4,4-dimethylcyclohexanol; and isolating or not isolating the first protected (2E)-1-(4-chlorophenyl)-2-(hydroxymethylene)4,4-dimethylcyclohexanol; and (d) reacting the first protected (2E)-1-(4-chlorophenyl)-2-(hydroxymethylene)-4,4-dimethylcyclohexanol and a first acid to provide 2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-carbaldehyde and isolating or not isolating the 2-(4-chlorophenyl)5,5-dimethylcyclohex-1-ene-1-carbaldehyde; (e) reacting 2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-carbaldehyde, ethyl 4-piperazin-1-ylbenzoate and a first reducing agent and isolating or not isolating the ethyl 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoate; (f) reacting ethyl 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoate and an aqueous third base, and isolating or not isolating the 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoic acid; and (g) reacting 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoic acid, 4-(((1R)-3-morpholin-4-yl-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, a first coupling reagent, and, optionally; a first auxiliary coupling reagent and isolating or not isolating the N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1- ((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide.
-
公开(公告)号:SG10201505540SA
公开(公告)日:2015-08-28
申请号:SG10201505540S
申请日:2011-07-15
Applicant: ABBOTT LAB
Inventor: SHEKHAR SHASHANK , FRANCZYK THADDEUS S , BARNES DAVID M , DUNN TRAVIS B , HAIGHT ANTHONY R , CHAN VINCENT S
Abstract: This disclosure is directed to: (a) processes for preparing an intermediate useful for the preparation of a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) an intermediate useful for the preparation of the compound and salts; and (c) pharmaceutical compositions comprising the intermediate or salts.
-
公开(公告)号:ZA201300250B
公开(公告)日:2014-06-25
申请号:ZA201300250
申请日:2013-01-10
Applicant: ABBOTT LAB
Inventor: SHEKHAR SHASHANK , BARNES DAVID M , HAIGHT ANTHONY R , FRANCZYK THADDEUS S , DUNN TRAVIS B , CHAN VINCENT S
IPC: B01J20060101
Abstract: The disclosure is directed to: (a) phosphacycle ligands; (b) methods of using such phosphacycle ligands in bond forming reactions; and (c) methods of preparing phosphacycle ligands.
-
公开(公告)号:PL2307393T3
公开(公告)日:2013-09-30
申请号:PL09767695
申请日:2009-06-18
Applicant: ABBOTT LAB
Inventor: FRANCZYK THADDEUS S II , HILL DAVID R , HAIGHT ANTHONY R , MCLAUGLIN MAUREEN ANN , SHEKHAR SHASHANK , YU SU , MEI JIANZHANG , WANG LEI
IPC: C07D295/13 , C07D295/155
-
公开(公告)号:DK2307393T3
公开(公告)日:2013-07-15
申请号:DK09767695
申请日:2009-06-18
Applicant: ABBOTT LAB
Inventor: FRANCZYK THADDEUS S II , HILL DAVID R , HAIGHT ANTHONY R , MCLAUGLIN MAUREEN ANN , SHEKHAR SHASHANK , YU SU , MEI JIANZHANG , WANG LEI
IPC: C07D295/13 , C07D295/155
-
-
-
-
-
-
-
-
-